MilliporeSigma
  • Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension.

Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension.

Clinical science (London, England : 1979) (2014-02-11)
Dylan Burger, Timothy L Reudelhuber, Aman Mahajan, Kelly Chibale, Edward D Sturrock, Rhian M Touyz
ABSTRACT

The somatic isozyme of ACE (angiotensin I-converting enzyme) comprises two distinct zinc-dependent catalytic domains with different substrate specificities for angiotensin I (cleaved selectively by the C-domain) and bradykinin (cleaved equally efficiently by both the N- and C-domains). Classical ACEIs (ACE inhibitors) target both domains, with side effects such as cough and angio-oedema being attributed, in part, to N-domain inhibition, probably through bradykinin accumulation. We questioned whether a novel C-domain-selective ACEI (lisW-S) has anti-hypertensive effects without influencing bradykinin status. AngII (angiotensin II)-dependent hypertension was studied in mice that express active human renin in the liver (TtRhRen). Compared with wild-type littermates, TtRhRen mice displayed cardiac hypertrophy and had significantly elevated SBP [systolic BP (blood pressure)] as determined by tail cuff sphygmomanometry (150±3 compared with 112±5 mmHg; P<0.05) and telemetry (163±3 compared with 112±2 mmHg; P<0.01). Treatment with the non-selective ACEI lisinopril (1 mg/kg of body weight per day via an osmotic mini-pump for 2 weeks) reduced SBP (127±3 compared with. 154±6; P<0.05). Similarly, treatment with the C-domain selective ACEI lisW-S (lisinopril-tryptophan; 3.6 mg/kg of body weight per day via an osmotic mini-pump for 2 weeks) reduced BP. Treatment with lisinopril or lisW-S significantly reduced levels of AngII in kidneys (~4-fold; P<0.001). Ang-(2-8) [angiotensin-2-8)] was significantly reduced by lisinopril, but not by lisW-S. Plasma bradykinin levels were significantly increased only in the lisinopril group. These data suggest that C-domain-selective ACEIs reduce BP and AngII levels similarly to classical ACEIs. C-domain-selective ACEIs have the potential to avoid undesirable effects on the bradykinin system common to classic ACEIs and may represent a novel approach to the treatment of hypertension.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Guanidine hydrochloride solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Guanidine hydrochloride solution, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Lisinopril dihydrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Angiotensin II human, ≥93% (HPLC), powder
Sigma-Aldrich
Guanidine hydrochloride, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Guanidine hydrochloride, anhydrous, free-flowing, Redi-Dri, ≥99%
SAFC
Guanidine hydrochloride
Sigma-Aldrich
Guanidine hydrochloride, ≥99.0% (AT)
Sigma-Aldrich
Guanidine hydrochloride, ≥99% (titration), organic base and chaeotropic agent
Sigma-Aldrich
Guanidine hydrochloride, for molecular biology, ≥99%
Sigma-Aldrich
Guanidine hydrochloride, ≥98%
Supelco
Lisinopril, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Lisinopril, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Lisinopril, ≥98% (HPLC)